Literature DB >> 30996326

Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Junfei Zhao1,2, Andrew X Chen1, Robyn D Gartrell3, Andrew M Silverman3, Luis Aparicio1,2, Tim Chu1,2, Darius Bordbar3, David Shan3, Jorge Samanamud4, Aayushi Mahajan4, Ioan Filip1, Rose Orenbuch1, Morgan Goetz5, Jonathan T Yamaguchi6, Michael Cloney6, Craig Horbinski6,7, Rimas V Lukas8, Jeffrey Raizer8, Ali I Rae9, Jinzhou Yuan2, Peter Canoll10, Jeffrey N Bruce4, Yvonne M Saenger11, Peter Sims2, Fabio M Iwamoto12, Adam M Sonabend13, Raul Rabadan14,15.   

Abstract

In the version of this article originally published, the graph in Extended Data Fig. 2c was a duplication of Extended Data Fig. 2b. The correct version of Extended Data Fig. 2c is now available online.

Entities:  

Year:  2019        PMID: 30996326     DOI: 10.1038/s41591-019-0449-8

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  9 in total

1.  Prognostic and Predictive Value of an Immunoscore Signature in Glioblastoma Multiform.

Authors:  Xiangjun Tang; Pengfei Xu; Ann Chen; Gang Deng; Shenqi Zhang; Lun Gao; Longjun Dai; Qianxue Chen
Journal:  Front Genet       Date:  2020-11-09       Impact factor: 4.599

Review 2.  Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity.

Authors:  Rosmely Hernandez; Thomas R Malek
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

Review 3.  Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas.

Authors:  Anudeep Yekula; Koushik Muralidharan; Zachary S Rosh; Anna E Youngkin; Keiko M Kang; Leonora Balaj; Bob S Carter
Journal:  Adv Biosyst       Date:  2020-06-02

4.  Stereotactic radiation therapy with concurrent immunotherapy for recurrent glioblastoma-hope or hype?

Authors:  Christina Tsien
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

5.  PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma.

Authors:  Carolina Noronha; Ana Sofia Ribeiro; Ricardo Taipa; Dina Leitão; Fernando Schmitt; Joaquim Reis; Cláudia Faria; Joana Paredes
Journal:  J Neurooncol       Date:  2022-01-23       Impact factor: 4.130

Review 6.  Microenvironmental Heterogeneity in Brain Malignancies.

Authors:  Lucas J M Perus; Logan A Walsh
Journal:  Front Immunol       Date:  2019-10-01       Impact factor: 7.561

7.  A Novel Prognostic Tool for Glioma Based on Enhancer RNA-Regulated Immune Genes.

Authors:  Wei Tian; Kegong Chen; Guangcan Yan; Xinhao Han; Yanlong Liu; Qiuju Zhang; Meina Liu
Journal:  Front Cell Dev Biol       Date:  2022-01-20

8.  Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.

Authors:  Patrick C Gedeon; Cosette D Champion; Kristen E Rhodin; Karolina Woroniecka; Hanna R Kemeny; Alexa N Bramall; Joshua D Bernstock; Bryan D Choi; John H Sampson
Journal:  Expert Rev Clin Pharmacol       Date:  2020-09-11       Impact factor: 5.045

Review 9.  Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges.

Authors:  Bo Qiu; Cassie Kline; Sabine Mueller
Journal:  Front Oncol       Date:  2021-06-30       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.